MD, PhD, Board Member, CEO
Per Agvald was born in 1971. He holds a MD and a PhD from Karolinska Institutet, Stockholm, Sweden. Per is an accomplished researcher in the field of NO-donors and as such participated in the discovery and development of the unique methods that formed the basis for the detection and characterization of Supernitro. He is also a senior consultant in psychiatry and an experienced people and organization development manager and lecturer.
Per has founded and served as CEO for several companies and is one of the founders and current principal owners of Attgeno. During his years as CEO for Attgeno, Per has led the company from the pre-clinical research phase to a clinical development company now entering clinical development phase II.
MD, PhD, Board Member, CMO (and deputy CEO)
Christofer was born in 1965. He is a senior consultant in urologic surgery at the new Karolinska University hospital where he mainly performs robotic and open surgery including extensive urinary reconstructions on severely ill patients with cancer. He is among medical students, interns and residents an appreciated lecturer in urologic surgery. Christofer also worked in cardiothoracic surgery and performed cardiac surgery procedures. In his role as a surgeon, Christofer has direct clinical experience in patients who suffer from different complications including acute postoperative pulmonary hypertension (aPH).
In combination with his clinical experience, Christofer also has extensive research experience (more than 25 years with over 40 published articles/book chapters), focusing on NO and its function in lung circulation and enhanced surgical recovery programs. He has previously worked as Senior Research Consultant at AstraZeneca with the development of new NO-donating drugs.
With his dual experience in clinical work and research, Christofer has a unique ability to understand the importance of a new and effective treatment for aPH. Christofer has close daily contact with the networks of Supernitro’s likely customers, anaesthesiologists, intensive care physicians and surgeons. With his unique profile, Christofer is an important link to bring Supernitro into the clinical reality. Christofer is one of the founders and current main owners in Attgeno.
MSc PhD, COO
Cecilia Kemi was born in 1976 and holds a MSc in molecular biology from Umeå university and a PhD in Medicine with focus on lung medicine from Karolinska instititet. She has 15 years of experience form the life science industry and has worked in various roles with increasing responsibility within preclinical and clinical drug development as well as medical affairs. Cecilia Kemi is an experienced project manager has worked both in larger pharmaceutical companies and in small start-up biotechnology companies within several indication areas including respiratory diseases, immunology and vaccines. Her broad experience overseeing substances in different stage of development brings valuable insight to the continued development of Attgenos drug candidates.
MD, PhD, Assoc. Prof., Senior Scientific Advisor
Kristofer Nilsson was born in 1981. He is a resident physician in anaesthesiology and intensive care at Örebro University Hospital, Sweden, and holds a PhD in physiology from Karolinska Institute with a dissertation in nitric oxide (NO) in pulmonary embolism in 2010. Kristofer is currently responsible for experimental animal research at the Dept. of Cardiothoracic and Vascular Surgery, Örebro University, Sweden, and supervisor of several PhD students. Kristofer has been involved in most of the experimental work leading to the development of Supernitro and was awarded the best intensive care-related experimental publication in 2017, on Supernitro´s protective effect in kidney injury, by the Swedish Intensive Care Society. His expertise in the field of NO research and vast experience in designing experimental studies are pivotal to pre-clinical advancement of Attgeno´s drug candidates.
MD, PhD, Assoc. Prof. , Consultant Medical Monitor
Mikael Holst was born 1956. He has exactly 30 years at Karolinska Institutet as Med School student, PhD graduate, post-doc training and a 10 years period as Director of Graduate Training and Associate Professor, before moving over to the Pharma Industry in September 2005. At Schering, Bayer-Schering, Wyatt and Pfizer, Mikael either worked for Medical Affairs or for Clinical Development in the role of Medical Advisor/Medical Monitor supporting the Nordic region, at times extended to responsibility for either the Baltic states and Russia or UK/Ireland.
Since 2015, Mikael has committed his services to small and middle-sized companies searching for support in either medical advice for marketed drugs or for new compounds in development. In April 2019, Mikael joined the clinical development team at Attgeno on a part-time basis.